Clinical Trials
24 trialsDevelopment and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)
Peking University First Hospital
PHEO
University Hospital, Rouen
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics
Peking Union Medical College Hospital
SNIPP
University Health Network, Toronto
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
Preoperative Alpha Blockade for Pheochromocytoma
University of California, Los Angeles
Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey
Pamukkale University
MPPGL
Peking Union Medical College Hospital
DOTATATE
Assistance Publique Hopitaux De Marseille
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
PheoCard
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Institutes of Health Clinical Center (CC)
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
Dovitinib in Neuroendocrine Tumors
Abramson Cancer Center at Penn Medicine
COMETETACTIC
Assistance Publique - Hôpitaux de Paris
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
University Hospital, Angers
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Molecular Insight Pharmaceuticals, Inc.